Gene · 8317
NIH grants1,079
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 1,079
Download this page as JSON| Grant | Title | CDC7 papers | Newest fiscal year |
|---|---|---|---|
| R35GM118053 | Regulatory Enzymes and Systems in Cell Cycle Control | 1 | 2025 |
| R35GM118109 | Mechanisms linking replication stress to genome instability in fission yeast | 1 | 2025 |
| R35GM119550 | Biology of RNA damage and repair | 1 | 2025 |
| R35GM122517 | Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology | 1 | 2025 |
| R35GM126900 | Mechanisms of chromatin and transcriptional regulation | 1 | 2025 |
| R35GM127026 | Cell Signaling and Cell Decisions | 1 | 2025 |
| R35GM127338 | The coordination of cell death and corpse clearance in Drosophila | 1 | 2025 |
| R35GM130345 | Renewal: Strategies and Methods for Complex Molecule Synthesis | 1 | 2025 |
| R35GM132090 | Mapping Fitness & Free Energy Landscapes of Proteins | 1 | 2025 |
| R35GM137996 | Novel cellular regulatory mechanisms governing SWI/SNF activity | 1 | 2025 |
| R35GM139610 | Understanding the mechanistic role of genome stability pathways in regulating cell homeostasis | 1 | 2025 |
| R35GM141159 | Signaling Mechanisms in Genome Maintenance | 1 | 2025 |
| R35GM142768 | Construction of Heteroarenes Through Single Atom Insertion Strategies | 1 | 2025 |
| R37AI039394 | Biochemical Mechanism of HIV DNA Integration | 1 | 2025 |
| R37CA240625 | Investigating p16 Loss in Pro-tumorigenic Metabolism | 1 | 2025 |
| R37CA244613 | Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer | 1 | 2025 |
| R37CA252050 | Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer | 1 | 2025 |
| R37CA258730 | Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance | 1 | 2025 |
| R50CA211206 | Cancer Pharmacologist and HTS Scientist | 1 | 2025 |
| RM1HG009490 | Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8317/grants?page=9